A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab for Angiosarcoma
Latest Information Update: 24 Nov 2023
At a glance
- Drugs Sintilimab (Primary)
- Indications Haemangiosarcoma
- Focus Therapeutic Use
- Acronyms SiARa
Most Recent Events
- 20 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 28 Dec 2021 Status changed from not yet recruiting to recruiting.
- 06 Sep 2021 New trial record